Net Loss Per Share

12 Months Ended

Dec. 31, 2024

14. Net Loss Per Share

The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of Common Stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of Common Stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.

The following table sets forth the computation of basic and diluted net loss per share:


	Year Ended December 31,
	2024			2023
Numerator:
Net loss attributable to ASP Isotopes shareholders	$	(35,113,240	)	$	(16,286,234	)
Denominator:
Weighted average common stock outstanding, basic and diluted		55,671,805			33,066,708
Net loss per share, basic and diluted	$	(0.63	)	$	(0.49	)

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:


	Year Ended December 31,
	2024		2023
Options to purchase common stock		2,731,000		2,766,000
Restricted stock		2,814,703		4,489,186
Warrants to purchase common stock		1,516,297		3,386,076
Total shares of common stock equivalents		7,062,000		10,641,262